Byron Lam, MD

Byron Lam, MD is professor of ophthalmology at the Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, where his research and clinical work focus on inherited retinal disease.

Articles by Byron Lam, MD

FDA priority review for tinlarebant: Byron Lam, MD, and Benjamin Bakall, MD, PhD, weigh in

ByByron Lam, MD,Benjamin Bakall, MD, PhD,Lucia Gambuzza

August 16th 2026

Byron Lam, MD, and Benjamin Bakall, MD, PhD, discuss what an FDA approval of tinlarebant could mean for the Stargardt disease type 1 standard of care.

FDA grants priority review to tinlarebant NDA for Stargardt disease type 1

ByByron Lam, MD,Lucia Gambuzza

Published: August 11th 2026 | Updated: August 12th 2026

FDA grants priority review to Belite Bio's tinlarebant NDA for Stargardt disease type 1, setting a February 2027 PDUFA date for a potential first STGD1 therapy.

Byron Lam, MD

Articles by Byron Lam, MD

FDA priority review for tinlarebant: Byron Lam, MD, and Benjamin Bakall, MD, PhD, weigh in

FDA grants priority review to tinlarebant NDA for Stargardt disease type 1

Latest Updated Articles